MarketCap
Ultralife Corporation ULBI
$ 5.19
0.58%
Facebook
X
Telegram
Ultralife Corporation Financial Ratios 2025-2008 | ULBI
Brief overview of Ultralife Corporation's valuation multiples
Ratios are assessed across five available annual reports in the 2018–2024 interval.
The valuation comparison uses P/E 13.25x (median 17.84x), EV/EBITDA 12.45x (median 12.45x), P/S 0.57x (median 0.57x). Ratios sit near their own comparison base, with an average deviation of 0% from five-year medians.
Current earnings relative to valuation equal about 7.5% on the 1/P/E measure. This is a valuation reference, not an expected payout.
End-period return metrics are ROE -4.5%, ROA -2.7%, ROCE -4.5%. Current return ratios are negative, materially weakening the fundamental profile.
Price, earnings and growth produce a PEG of 0.46x. A value below one indicates moderate pricing relative to expected growth.
The cash cycle accelerated by 24.4 days to 153.2 days. Less capital is tied up in operations.
Overall assessment
Ultralife Corporation trades near its familiar ratio range. A new earnings or profitability trend is needed to change the view.
Annual Financial Ratios Ultralife Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-18.5 | 13.2 | 21.4 | -542.0 | -370.3 | 17.8 | 21.3 | 5.0 | 14.4 | 23.7 | 31.8 | -27.7 | -76.8 | -33.3 | -34.6 | -13.7 | -12.9 | - |
P/S |
0.6 | 0.5 | 1.0 | 0.5 | 0.9 | 0.9 | 1.0 | 1.4 | 1.3 | 1.0 | 1.2 | 0.9 | 0.9 | 0.5 | 0.5 | - | - | - |
EPS |
-35 | 38 | 0.4 | 0.1 | 0.1 | 0.3 | 33 | 1.6 | 0.5 | 0.2 | 0.2 | -0.1 | -0.1 | -0.1 | -0.1 | -0.4 | -0.5 | - |
EV (Enterprise Value) |
186 M | 163 M | 197 M | 111 M | 120 M | 104 M | 138 M | 115 M | 110 M | 89.4 M | 92.2 M | 56.6 M | 71.6 M | 67.9 M | 94.3 M | 79.8 M | 113 M | -1.88 M |
EBITDA per Share |
-0.12 | 0.79 | 0.83 | 0.28 | 0.22 | 0.543 | 0.641 | 0.562 | 0.573 | 0.266 | 0.222 | -0.0752 | -0.0255 | 0.00707 | 0.393 | 0.91 | 0.02 | - |
EV/EBITDA |
-97.1 | 12.5 | 14.7 | 24.2 | 9.4 | 9.9 | 11.9 | 11.2 | 10.3 | 17.8 | 21.4 | -31.1 | -123.6 | 354.4 | 9.8 | 5.1 | 357.5 | - |
PEG |
-2.09 | 0.46 | 0.66 | 76.5 | -35.27 | -59.79 | -0.27 | 0.02 | 0.13 | 0.85 | 0.13 | 0.2 | -1.73 | -1.33 | -0.52 | - | - | - |
P/B |
0.8 | 0.6 | 1.2 | 0.6 | 0.7 | 0.8 | 1.0 | 1.2 | 1.4 | 1.2 | 1.4 | 0.8 | 1.0 | 0.7 | 1.0 | 0.7 | - | - |
P/CF |
9.9 | 5.0 | 79.9 | -51.1 | 20.0 | 5.0 | -12.0 | 18.7 | 18.8 | 12.9 | 16.2 | 29.1 | 11.6 | 25.6 | 8.4 | 7.7 | 58.8 | - |
ROE % |
-4.54 | 4.71 | 5.74 | -0.10 | -0.20 | 4.48 | 4.74 | 23.83 | 9.66 | 5.16 | 4.34 | -2.94 | -1.26 | -2.17 | -2.84 | -8.38 | -11.83 | - |
ROA % |
-2.72 | 2.86 | 4.04 | -0.07 | -0.15 | 3.80 | 3.60 | 20.76 | 7.87 | 4.14 | 3.52 | -2.41 | -1.03 | -1.64 | -2.06 | -5.38 | - | - |
ROCE % |
-4.54 | 7.44 | 7.56 | 0.11 | 0.03 | 4.79 | 5.78 | 6.23 | 7.81 | 5.13 | 4.92 | -1.89 | -0.80 | -0.15 | 3.19 | 15.12 | -4.54 | - |
Current Ratio |
2.5 | 2.6 | 3.4 | 3.2 | 3.8 | 3.4 | 4.1 | 4.5 | 4.3 | 4.4 | 4.8 | 5.1 | 4.9 | 3.2 | 2.8 | - | - | - |
DSO |
60.4 | 67.8 | 68.5 | 66.5 | 76.7 | 71.3 | 102.9 | 67.0 | 62.5 | 58.3 | 55.4 | 63.0 | 67.9 | 77.8 | 57.2 | - | - | - |
DIO |
132.5 | 139.8 | 127.4 | 132.5 | 152.2 | 131.0 | 143.6 | 135.3 | 162.0 | 149.3 | 163.7 | 202.0 | 169.2 | 152.0 | 122.7 | 50.3 | - | - |
DPO |
39.7 | 38.1 | 41.9 | 46.1 | 51.2 | 50.4 | 45.3 | 58.8 | 54.1 | 46.4 | 44.6 | 54.2 | 45.8 | 56.8 | 48.3 | 24.8 | - | - |
Operating Cycle |
192.9 | 207.7 | 195.9 | 199.0 | 228.8 | 202.3 | 246.5 | 202.4 | 224.6 | 207.6 | 219.1 | 265.0 | 237.1 | 229.8 | 180.0 | 50.3 | - | - |
Cash Conversion Cycle |
153.2 | 169.6 | 154.1 | 152.8 | 177.6 | 152.0 | 201.2 | 143.6 | 170.5 | 161.2 | 174.5 | 210.8 | 191.3 | 172.9 | 131.6 | 25.5 | - | - |
All numbers in USD currency
Quarterly Financial Ratios Ultralife Corporation
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-3 | -0.07 | 0.05 | 0.02 | - | 0.02 | 0.18 | 0.08 | - | 0.08 | 0.03 | 0.03 | - | 0.03 | 0.03 | -0.01 | - | 0.05 | 5 | 4 | - | 3 | 10 | 7 | - | 6 | 14 | 0.03 | - | 0.09 | 0.1 | 0.14 | - | 0.07 | 0.07 | 0.11 | - | 0.07 | 0.03 | 0.02 | - | 0.07 | 0.05 | 0.03 | - | -0.02 | -0.08 | -0.07 | - | 0.04 | -0.12 | 0.02 | - | 0.1 | -0.18 | -0.09 | - | 0.08 | 0.03 | -0.33 |
EBITDA per Share |
0.05 | - | 0.2 | 0.26 | - | 0.08 | 0.28 | 0.29 | - | 0.18 | 0.27 | 0.05 | - | 0.01 | 0.1 | 0.03 | - | - | 0.11 | 0.11 | - | 0.08 | 0.18 | 0.13 | - | 0.12 | 0.23 | 0.06 | - | 0.13 | 0.13 | 0.18 | - | 113 | 118 | 0.15 | - | 0.11 | 0.07 | 0.03 | - | 0.19 | 0.12 | 0.05 | - | 0.12 | 0.01 | -0.02 | - | 171 | -13.6 | 70.5 | - | 0.25 | -0.07 | -0.02 | - | 0.25 | 0.28 | -0.17 |
ROE % |
0.77 | 1.31 | 4.42 | 6.03 | 4.66 | 5.75 | 8.35 | 5.83 | 3.59 | 3.38 | 2.72 | -0.21 | 0.09 | -0.41 | 0.48 | 0.61 | 0.76 | 1.11 | 3.02 | 3.24 | 2.67 | 3.49 | 5.20 | 4.17 | 3.26 | 4.61 | 5.35 | 5.35 | 4.96 | 6.35 | 6.38 | 6.91 | 4.86 | 6.36 | 5.62 | 4.68 | 2.59 | 4.18 | 3.87 | 4.02 | 3.58 | 3.13 | -0.34 | -3.32 | -4.13 | -3.25 | -5.62 | -3.14 | -1.35 | 0.93 | -4.25 | -3.48 | -4.06 | -2.20 | -3.89 | -7.35 | -5.31 | 1.86 | 0.60 | -7.77 |
ROA % |
0.48 | 0.83 | 3.13 | 4.33 | 3.50 | 4.25 | 6.01 | 4.06 | 2.46 | 2.32 | 1.46 | -0.88 | -0.67 | -0.08 | 0.06 | 0.55 | 0.66 | 0.95 | 2.59 | 2.76 | 2.27 | 2.89 | 4.15 | 3.24 | 2.48 | 3.64 | 4.37 | 4.59 | 4.29 | 5.42 | 5.38 | 5.74 | 3.96 | 5.16 | 4.56 | 3.78 | 2.08 | 3.37 | 3.13 | 3.26 | 2.90 | 2.54 | -0.30 | -2.73 | -3.39 | -2.67 | -4.60 | -2.57 | -1.10 | 0.62 | -3.34 | -2.58 | -3.06 | -1.71 | -2.99 | -5.39 | -3.86 | 1.35 | 0.44 | -5.64 |
ROCE % |
3.26 | 3.81 | 7.44 | 8.96 | 6.47 | 8.22 | 10.90 | 7.99 | 4.84 | 4.33 | 3.25 | -0.06 | -0.08 | -0.74 | 0.69 | 0.82 | 1.07 | 1.67 | 4.29 | 4.65 | 3.84 | 5.03 | 7.20 | 5.73 | 4.46 | 5.90 | 6.27 | 5.75 | 5.25 | 6.84 | 7.08 | 7.84 | 5.59 | 7.26 | 6.40 | 5.44 | 3.11 | 4.89 | 4.45 | 4.96 | 4.25 | 4.17 | 0.56 | -2.20 | -3.44 | -2.61 | -4.93 | -2.61 | -1.08 | 1.17 | -3.43 | -2.69 | -3.17 | -1.18 | 0.48 | -0.82 | 0.83 | 1.99 | 3.91 | -5.07 |
Current Ratio |
2.4 | 2.6 | 2.7 | 2.6 | 2.6 | 4.6 | 4.7 | 3.5 | 3.4 | 3.2 | 3.1 | 3.1 | 3.2 | 3.2 | - | 3.7 | 3.8 | 7.5 | 7.9 | 7.4 | 6.6 | 6.6 | 6.6 | 6.6 | 4.2 | 4.2 | 4.2 | 4.2 | 7.4 | 7.4 | 7.4 | 7.4 | 5.4 | 5.4 | 5.4 | 5.4 | 5.0 | 5.0 | 5.0 | 5.0 | 5.3 | 5.3 | 5.3 | 5.3 | 5.6 | 5.6 | 5.6 | 5.6 | 5.5 | 5.5 | 5.5 | 5.5 | - | - | - | - | - | - | - | - |
DSO |
62.9 | 66.5 | 64.2 | 58.8 | - | 75.2 | 70.4 | 73.0 | - | 64.5 | 56.7 | 74.7 | - | 36.9 | 32.5 | 64.8 | - | 73.3 | 64.5 | 70.6 | - | 78.9 | 67.3 | 90.4 | - | 99.9 | 93.5 | 111.4 | - | 71.9 | 63.9 | 60.7 | - | 63.5 | 67.1 | 57.6 | - | 61.3 | 59.0 | 53.9 | - | 54.8 | 55.0 | 54.1 | - | 64.2 | 67.8 | 76.2 | - | 63.8 | 75.2 | 76.3 | - | 72.9 | 102.0 | 67.7 | - | 51.6 | 42.1 | - |
DIO |
134.5 | 139.7 | 121.5 | 119.1 | - | 144.2 | 123.7 | 128.9 | - | 142.3 | 132.7 | 164.9 | - | 70.1 | 67.8 | 135.6 | - | 152.3 | 129.3 | 134.6 | - | 144.1 | 124.9 | 143.1 | - | 138.3 | 132.3 | 173.9 | - | 145.9 | 127.8 | 142.1 | - | 162.4 | 175.1 | 150.0 | - | 157.0 | 147.9 | 149.5 | - | 165.3 | 165.9 | 172.9 | - | 205.6 | 216.7 | 217.2 | - | 167.0 | 186.4 | 175.8 | - | 154.3 | 194.6 | 142.6 | - | 123.5 | 101.1 | - |
DPO |
46.7 | 39.5 | 39.1 | 37.0 | - | 37.8 | 33.4 | 36.9 | - | 49.1 | 53.3 | 65.3 | - | 27.2 | 20.9 | 41.0 | - | 51.4 | 46.0 | 50.4 | - | 55.4 | 48.0 | 49.9 | - | 43.6 | 41.7 | 63.8 | - | 63.3 | 55.5 | 54.1 | - | 54.2 | 58.5 | 48.4 | - | 48.8 | 46.0 | 43.6 | - | 45.1 | 45.2 | 46.7 | - | 55.1 | 58.1 | 58.5 | - | 45.2 | 50.5 | 57.4 | - | 57.7 | 72.8 | 54.8 | - | 48.6 | 39.8 | - |
Operating Cycle |
- | 206.2 | 185.8 | 177.9 | - | 219.4 | 194.2 | 201.8 | - | 206.8 | 189.4 | 239.6 | - | 107.0 | 100.3 | 200.4 | - | 225.6 | 193.8 | 205.3 | - | 223.0 | 192.2 | 233.5 | - | 238.2 | 225.7 | 285.4 | - | 217.8 | 191.7 | 202.8 | - | 225.9 | 242.2 | 207.6 | - | 218.2 | 206.9 | 203.4 | - | 220.1 | 220.9 | 226.9 | - | 269.8 | 284.5 | 293.5 | - | 230.8 | 261.6 | 252.1 | - | 227.2 | 296.6 | 210.3 | - | 175.1 | 143.3 | - |
Cash Conversion Cycle |
- | 166.8 | 146.7 | 141.0 | - | 181.6 | 160.7 | 164.9 | - | 157.7 | 136.1 | 174.3 | - | 79.8 | 79.4 | 159.3 | - | 174.2 | 147.8 | 154.9 | - | 167.6 | 144.2 | 183.6 | - | 194.6 | 184.0 | 221.5 | - | 154.4 | 136.2 | 148.7 | - | 171.7 | 183.8 | 159.2 | - | 169.4 | 161.0 | 159.8 | - | 175.0 | 175.7 | 180.2 | - | 214.7 | 226.4 | 234.9 | - | 185.6 | 211.1 | 194.8 | - | 169.5 | 223.9 | 155.5 | - | 126.5 | 103.5 | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Ultralife Corporation, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
USA
Britain
China
